FREE RAC Premarketing and Clinical Development Questions and Answers

Question 1

A sponsor submits an Investigational New Drug (IND) application for a Phase 1 study.
The FDA issues a clinical hold 25 days after submission.
Which of the following is the MOST likely reason for the clinical hold?

Accepted Answer

The Investigator's Brochure is found to be misleading or materially incomplete.

Answer

The proposed patient population is too small to achieve statistical significance.

Answer

The sponsor has not finalized the commercial manufacturing process.

Answer

The Phase 3 clinical trial protocol has not yet been submitted for review.

Question 2

A clinical investigator is preparing for a new industry-sponsored drug trial. By signing the Form FDA 1572, the investigator is making a legally binding commitment to the sponsor to perform which of the following actions?

Accepted Answer

Ensure the study is conducted according to the protocol and personally supervise the overall conduct of the trial.

Answer

Guarantee a specific number of subjects will be enrolled at their site.

Answer

Personally conduct all study-related procedures and assessments.

Answer

Secure marketing approval for the investigational product upon study completion.

Question 3

Which of the following is a required basic element of informed consent for a clinical trial, as specified in 21 CFR 50.25?

Accepted Answer

A disclosure of appropriate alternative procedures or courses of treatment, if any.

Answer

A statement that the Institutional Review Board (IRB) is a government entity.

Answer

A guarantee that the subject will personally benefit from participating in the research.

Answer

The complete curriculum vitae of the principal investigator.

Question 4

A medical device company plans to conduct a clinical study of a novel implantable cardiac defibrillator. The device is intended to sustain human life. According to 21 CFR 812, what is the regulatory status of this investigation and what is required before initiating the study?

Accepted Answer

Significant risk; both IRB approval and an approved Investigational Device Exemption (IDE) from the FDA are required.

Answer

Non-significant risk; only IRB approval is required.

Answer

Exempt from IDE regulations; no IRB or FDA approval is needed.

Answer

Significant risk; only an approved IDE from the FDA is required.

Question 5

A pharmaceutical company is developing a new drug for a serious condition with no available therapy. Preliminary clinical evidence suggests the drug may demonstrate a substantial improvement over existing standards of care on a clinically significant endpoint. Which expedited program would be MOST appropriate for the sponsor to request?

Accepted Answer

Breakthrough Therapy Designation

Answer

Fast Track Designation

Answer

Accelerated Approval

Answer

Priority Review

Question 6

In the context of Good Clinical Practice (GCP), which of the following is a primary responsibility of a clinical trial investigator?

Accepted Answer

Protecting the rights, safety, and well-being of trial subjects.

Answer

Ensuring the commercial viability of the investigational product.

Answer

Drafting the initial Investigational New Drug (IND) application for the sponsor.

Answer

Verifying that all clinical trial participants are adequately compensated for their time.

A sponsor submits an Investigational New Drug (IND) application for a Phase 1 study.The FDA issues a clinical hold 25 days after submission.Which of the following is the MOST likely reason for the clinical hold?

A sponsor submits an Investigational New Drug (IND) application for a Phase 1 study.
The FDA issues a clinical hold 25 days after submission.
Which of the following is the MOST likely reason for the clinical hold?